An Open-Label, Multicenter Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin in US Veterans with Genotype 1 Chronic Hepatitis C Infection: Efficacy and Safety Results of TOPAZ-VA
Publication
, Conference
Fuchs, M; Morgan, TR; Charafeddine, M; Brau, N; Schmidt, WN; Kozal, M; Naggie, S; Cheung, R; Pilot-Matias, T; Yu, Y; Richards, K; Mullally, V ...
Published in: HEPATOLOGY
October 1, 2016
Duke Scholars
Published In
HEPATOLOGY
EISSN
1527-3350
ISSN
0270-9139
Publication Date
October 1, 2016
Volume
64
Start / End Page
488A / 488A
Location
Boston, MA
Publisher
WILEY
Conference Name
67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD)
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics
Citation
APA
Chicago
ICMJE
MLA
NLM
Fuchs, M., Morgan, T. R., Charafeddine, M., Brau, N., Schmidt, W. N., Kozal, M., … Toro, D. H. (2016). An Open-Label, Multicenter Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin in US Veterans with Genotype 1 Chronic Hepatitis C Infection: Efficacy and Safety Results of TOPAZ-VA. In HEPATOLOGY (Vol. 64, pp. 488A-488A). Boston, MA: WILEY.
Fuchs, Michael, Timothy R. Morgan, Mariem Charafeddine, Norbert Brau, Warren N. Schmidt, Michael Kozal, Susanna Naggie, et al. “An Open-Label, Multicenter Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin in US Veterans with Genotype 1 Chronic Hepatitis C Infection: Efficacy and Safety Results of TOPAZ-VA.” In HEPATOLOGY, 64:488A-488A. WILEY, 2016.
Fuchs M, Morgan TR, Charafeddine M, Brau N, Schmidt WN, Kozal M, et al. An Open-Label, Multicenter Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin in US Veterans with Genotype 1 Chronic Hepatitis C Infection: Efficacy and Safety Results of TOPAZ-VA. In: HEPATOLOGY. WILEY; 2016. p. 488A-488A.
Fuchs, Michael, et al. “An Open-Label, Multicenter Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin in US Veterans with Genotype 1 Chronic Hepatitis C Infection: Efficacy and Safety Results of TOPAZ-VA.” HEPATOLOGY, vol. 64, WILEY, 2016, pp. 488A-488A.
Fuchs M, Morgan TR, Charafeddine M, Brau N, Schmidt WN, Kozal M, Naggie S, Cheung R, Pilot-Matias T, Yu Y, Richards K, Mullally V, Cohen DE, Monto A, Toro DH. An Open-Label, Multicenter Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin in US Veterans with Genotype 1 Chronic Hepatitis C Infection: Efficacy and Safety Results of TOPAZ-VA. HEPATOLOGY. WILEY; 2016. p. 488A-488A.
Published In
HEPATOLOGY
EISSN
1527-3350
ISSN
0270-9139
Publication Date
October 1, 2016
Volume
64
Start / End Page
488A / 488A
Location
Boston, MA
Publisher
WILEY
Conference Name
67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD)
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics